Skip to main content

Funicular Fund, LP's Form 4 filing

Oruka Therapeutics, Inc. (ORKA) · filed Apr 12, 2022

Accession no.
0000921895-22-001225
Filed
Apr 12, 2022, 7:31 PM ET
Trade date
Apr 8-12, 2022
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions. Open-market purchases total $242.7K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Funicular Fund, LPCIK 0001752618Other: See Footnote 1
Ma-Weaver JacobCIK 0001922140Other: See Footnote 1

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 8, 2022Common StockPPurchaseAcquired+30,660$2.31F2+$70,852.192,079,637Direct
Apr 11, 2022Common StockPPurchaseAcquired+4,655$2.32+$10,776.332,084,292Direct
Apr 12, 2022Common StockPPurchaseAcquired+69,398$2.32F3+$161,100.522,153,690Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Represents a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $2.3050 to $2.3350, inclusive of brokerage commissions. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F3

Represents a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $2.3050 to $2.3250, inclusive of brokerage commissions. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)